Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)-Reference-Cited by-同舟云学术

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)

Published:2009-05 Issue:5 Volume:20 Page:835-841
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Takeda K.,Negoro S.,Tamura T.,Nishiwaki Y.,Kudoh S.,Yokota S.,Matsui K.,Semba H.,Nakagawa K.,Takada Y.,Ando M.,Shibata T.,Saijo N.

Funder

Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/5/835/351476/mdn705.pdf

Reference32 articles.

1. Global cancer statistics in the year 2000;Parkin;Lancet Oncol,2001

2. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial;Dancey;Lung Cancer,2004

3. Chemotherapeutic management of stage IV non-small cell lung cancer;Socinski;Chest,2003

4. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

5. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX 320 Non-Small Cell Lung Cancer Study Group;Fossella;J Clin Oncol,2000

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nomogram for the prediction of the survival of patients with advanced non‐small cell lung cancer and interstitial lung disease;Cancer Medicine;2023-03-31

2. First and Second Line Chemotherapeutic Regimens for Non-Small Cell Lung Carcinomas - The Efficacy of Platinum, Non-Platinum and Combination Therapy: A Literature Review;Cureus;2020-11-22

3. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non–Small-cell Lung Cancer: Real World Experience in Argentina;Clinical Lung Cancer;2020-09

4. Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis;Cancer Chemotherapy and Pharmacology;2020-06-12

5. History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group;Japanese Journal of Clinical Oncology;2020-03-02